Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adriana de Souza Azevedo has a total of 363 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An open label, uncontrolled clinical trial of immunogenicity and safety of yellow fever vaccine in adults with chronic kidney disease as compared to immunocompetent

    by Amanda Caroline Ribeiro Sales, Camila de Melo Picone, Adriana de Souza Azevedo Soares, Sheila Maria Barbosa de Lima, Anna Nishiya, Pedro Henrique Theotonio de Mesquita Pacheco, Paula Keiko Sato, Camila Cristina Martini Rodrigues, Marta Heloisa Lopes, Amanda Nazareth Lara, et al.

  • Open Access

    Immunogenicity and safety of yellow fever vaccine in adults with chronic kidney disease

    by Ana Marli Christovam Sartori, Amanda Caroline Ribeiro Sales, Camila Melo Picone, Adriana de Souza Azevedo, Sheila Maria Barbosa de Lima, Anna Shoko Nishiya Oshiro, Pedro H. M. Pacheco, Paula Keiko Sato, Camila Cristina Martini Rodrigues, Marta Heloisa Lopes, et al.

    Background: During a yellow fever (YF) epidemic in Brazil, vaccination campaigns targeting the entire population in the affected areas were conducted, bringing up an opportunity to prospectively evaluate YF vaccine’s immunogenicity and safety in adults with chronic kidney disease (CKD) compared to healthy adults.Methods: Open-label trial involved adults aged ≥18 years with CKD on dialysis (CKD-D) or not (CKD-ND) and healthy, who denied previous YF vaccination. All them received a YF vaccine standard dose. Adverse events (AE) were monitored within 15 days after vaccination. Neutralizing antibodies were measured by microneutralization test with 50% reduction of lysis plaques (micro-PRN50). Viremia was evaluated by RT-PCR.Results: 154 participants were included: 54 CKD-D, 41 with CKD-ND and 59 healthy. Median age was 50, 61 and 47 years, respectively. Ten days after vaccination (D10), seropositivity was significantly lower in CKD (CKD-ND, 62.3%; CKD-D, 48%) than in healthy (86.7%) and CKD participants had lower antibody geometric mean titers (GMT). On D30, GMT increased in all three groups, and seropositivity rates and GMT of CKD and healthy groups were not significantly different. On D365, most participants in the three groups persisted seropositive, with a GMT decrease in all three groups, without significant differences. On D10, viremia was detected in 28.8% of CKD-D; 32.3% of CKD-ND, and 28.9% of healthy, without significant difference between groups, but CKD participants had lower viremia. Healthy participants more frequently reported AE (66.7%) than CKD-ND (48.5%) and CKD-D (48.8%). Most common AE were headache (32.7%), myalgia (28.4%) and injection site pain (25.3%). Conclusions. CKD adults had a robust although delayed neutralizing antibody response to YF vaccine. The vaccine was well-tolerated by adults with CKD, but the sample size did not allow conclusions on vaccine-related severe AE.

  • Open Access

    Correction: Denani et al. Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling. Pathogens 2025, 14, 1129

    by Caio Bidueira Denani, Bruno Pimenta Setatino, Denise Pereira, Ingrid Siciliano Horbach, Adriana Souza Azevedo, Gabriela Coutinho, Clara Lucy Ferroco, Janaína Xavier, Robson Leite, Ewerton Santos, et al.

    There was an error in the original publication


  • Open Access

    Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling

    by Caio Bidueira Denani, Bruno Pimenta Setatino, Denise Pereira, Ingrid Siciliano Horbach, Adriana Souza Azevedo, Gabriela Coutinho, Clara Lucy Ferroco, Janaína Xavier, Robson Leite, Ewerton Santos, et al.

    Neutralizing antibodies (nAbs) are key indicators of protection against SARS-CoV-2, and their measurement remains essential for monitoring vaccine responses and population immunity. While the plaque reduction neutralization test (PRNT) is the gold standard, it relies on replicative viruses and is not suited for high-throughput applications. Here, both an in-house and a commercial pseudovirus-based neutralization (PBN) assay were standardized and compared with PRNT to assess performance and concordance. The in-house PBN employed a VSV-ΔG pseudovirus encoding NanoLuc and displaying the SARS-CoV-2 Spike from the Wuhan or Omicron BA.1 variants in HEK293T-hACE2 cells, whereas the commercial assay (Integral Molecular, Philadelphia, PA, USA) used a lentiviral backbone with Renilla or GFP reporters and Wuhan or Omicron XBB.1.5/XBB.1.9 Spikes in Vero E6-ACE2-TMPRSS2 cells. Both assays showed strong correlations with PRNT, the commercial assay; moreover, they offered superior reproducibility and scalability, while the in-house version provided a cost-effective alternative suitable for BSL-2 settings. A total of 600 serum samples from vaccinated individuals were analyzed by commercial PBN at collection time points, from pre-vaccination to twelve months post–second dose, enabling large-scale screening, revealing marked differences in neutralization between Wuhan and Omicron XBB.1.5/1.9, and allowing unbiased classification of low, medium, and high responders using k-means clustering. The geometric mean titers (log10 GMT) highlighted a ~1.5 log10 (eightfold) reduction in neutralizing activity against Omicron, reflecting antibody waning and antigenic drift. Altogether, this study integrates assay standardization, PRNT comparison, and large-scale immune profiling, establishing a robust framework for harmonized pseudovirus-based neutralization testing.


  • Open Access

    Third Booster Half Dose of ChAdOx1-nCov-19 Is Effective, Safe, and Induces Long-Duration Humoral and Cellular Immune Response to Omicron: 1-Year Follow-Up of Viana Study

    by Nésio Fernandes de Medeiros-Junior, Maria da Penha Gomes Gouvea, Luiz Antônio Bastos Camacho, Daniel Antunes Maciel Villela, Sheila Maria Barbosa de Lima, Waleska Dias Schwarcz, Adriana Souza Azevedo, Lauro Ferreira Pinto Neto, Carla Magda Allan Santos Domingues, Rosilene Nilo dos Santos Fantoni, et al.

    Background: Dose-sparing approaches can be effective in maintaining immunogenicity and safety while expanding vaccine coverage. We previously demonstrated that a half dose of ChAdOx1 nCoV-19 is as effective and immunogenic for primary vaccination. Methods: This non-inferiority, non-randomized controlled trial evaluated the effectiveness, humoral, and cellular immune responses of a third booster dose—comparing half-dose and full-dose regimens—in individuals aged 18–49 years, with a 1-year follow-up. Results: A total of 2801 participants were enrolled: 2352 received half doses and 449 received full doses. The incidence rate of COVID-19 was 225.0 per 1000 person-years in the half-dose group and 173.8 in the full-dose group, with no significant difference in effectiveness (β = −0.05; 95% CrI: −0.24 to 0.15). No deaths occurred, and hospitalization rates were similar. In a subsample (n = 558), anti-S IgG levels peaked 28 days post-dose and declined by day 180 after the primary series [175 (121–252) vs. 121 (71–208) GMT, p < 0.001], but remained elevated after the booster [192.1 (124–297) vs. 550 (380–797) GMT, p < 0.001]. Booster antibody levels were similar between groups [592.4 (318–1140) vs. 550 (380–797) GMT]. The half-dose group showed high titers against Omicron and robust T/B-cell responses (e.g., EMCD4, EMCD8, IFN+CD4+, CD19+TNF+). Conclusions: Fractional half dose of ChAdOx nCov-19 was effective and non-inferior to a full booster dose. Homologous regimen with 3 half doses or 3 full doses induced a similar increase in antibody titers and robust cellular response. ClinicalTrials.gov (NCT05059106).


  • Open Access

    Evolution of the PRNT: Merging tradition and innovation to set the gold standard in the era of automation

    by Caio Denani, Ingrid Horbach, Bruno Setatino, Adriana Azevedo, Sheila Lima, Waleska Schwarcz, Ivanildo Sousa

    The plaque reduction neutralization test (PRNT) is the gold standard for quantifying neutralizing antibodies owing to its high sensitivity and specificity. Widely used in seroepidemiological studies and vaccine development, PRNT is limited by labor-intensive procedures, reliance on highly skilled staff, and susceptibility to human bias during manual plaque counting. These limitations hinder reproducibility, throughput, and cross-laboratory standardization. This review summarizes recent efforts to automate PRNT workflows to address these issues. However, automation adoption is often constrained by high costs and the need for regulatory frameworks to ensure data integrity. Advancements in tailored hardware and software to diverse laboratory contexts are essential to maintaining PRNT's role in immunological assessments, bridging seroneutralizing methodologies with modern automation, and making automated methods more accessible. This review outlines the key requirements for PRNT's continued evolution.


  • Open Access

    Safety and Immunogenicity of the Attenuated Yellow Fever Vaccine in Several Neotropical Primate Species

    by Nayara Ferreira de Paula, André Duarte Vieira, Daniel Oliveira dos Santos, Lucas dos Reis de Souza, Carlyle Mendes Coelho, Herlandes Penha Tinoco, Paula Cristina Senra Lima, Rafael Otávio Cançado Motta, Valéria Do Socorro Pereira, Marcelo Pires Nogueira de Carvalho, et al.

    Background/Objective: Yellow fever (YF) is an acute infectious disease caused by the yellow fever virus which is transmitted by mosquitoes. Neotropical primates are susceptible to infection, which is often presented as epizootic outbreaks. The aim was to evaluate and characterize the immune response against YF in different species of neotropical primates from the Belo Horizonte Zoo. Methods: Vaccine 17DD was administered to 24 neotropical primates, with a single subcutaneous dose. Clinical exams, RNAemia, and detection of IgG and neutralizing antibodies against YFV were performed. In addition, an ethogram was performed to assess clinical changes and animal welfare. Results: At 4 days post-vaccination, RNAemia was detected in nine animals. There was seroconversion and persistence of immune response in Alouatta guariba clamitans, Sapajus xanthosternos, Saguinus imperator and Aotus infulatus. However, the vaccine was not immunogenic for Lagothrix cana. In Pithecia irrorata seroconversion did not persist long term, while the Ateles sp. had a transient immune response. No significant clinical manifestations were observed in any of the vaccinated animals. Conclusions: This study demonstrated a safe, immunogenic and persistent immune response induced by the attenuated 17DD vaccine strain in A. guariba clamitans, S. xanthosternos, S. imperator, and A. infulatus.


  • Micro-Focus Reduction Neutralization Tests (mFRNT) for Neutralizing Antibody (Nab) Quantification Against Yellow Fever Virus

    by Adriana de Souza Azevedo, Nathalia dos Santos Alves

    Although the plaque reduction neutralization test (PRNT) is considered the reference for measuring neutralizing antibodies for Yellow fever virus (YFV), the micro-focus reduction neutralization test (mFRNT) presents many advantages including a higher throughput, a reduced incubation time, and allows the automatic foci count. So, here we describe a detailed mFRNT method that provides a faster neutralization test essential for non-clinical and clinical studies and vaccine design.

  • Open Access

    Impact of HIV-Related Immune Impairment of Yellow Fever Vaccine Immunogenicity in People Living with HIV—ANRS 12403

    by Diogo Gama Caetano, Thais Stelzer Toledo, Ana Carolina Souza de Lima, Carmem Beatriz Wagner Giacoia-Gripp, Dalziza Victalina de Almeida, Sheila Maria Barbosa de Lima, Adriana de Souza Azevedo, Michelle Morata, Beatriz Grinsztejn, Sandra Wagner Cardoso, et al.

    The yellow fever (YF) vaccine is one of the safest and most effective vaccines currently available. Still, its administration in people living with HIV (PLWH) is limited due to safety concerns and a lack of consensus regarding decreased immunogenicity and long-lasting protection for this population. The mechanisms associated with impaired YF vaccine immunogenicity in PLWH are not fully understood, but the general immune deregulation during HIV infection may play an important role. To assess if HIV infection impacts YF vaccine immunogenicity and if markers of immune deregulation could predict lower immunogenicity, we evaluated the association of YF neutralization antibody (NAb) titers with the pre-vaccination frequency of activated and exhausted T cells, levels of pro-inflammatory cytokines, and frequency of T cells, B cells, and monocyte subsets in PLWH and HIV-negative controls. We observed impaired YF vaccine immunogenicity in PLWH with lower titers of YF-NAbs 30 days after vaccination, mainly in individuals with CD4 count 3. At the baseline, those individuals were characterized by having a higher frequency of activated and exhausted T cells and tissue-like memory B cells. Elevated levels of those markers were also observed in individuals with CD4 count between 500 and 350 cells/mm3. We observed a negative correlation between the pre-vaccination level of CD8+ T cell exhaustion and CD4+ T cell activation with YF-NAb titers at D365 and the pre-vaccination level of IP-10 with YF-NAb titers at D30 and D365. Our results emphasize the impact of immune activation, exhaustion, and inflammation in YF vaccine immunogenicity in PLWH.


  • Open Access

    Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults

    by Laise Rodrigues Reis, Ismael Artur Costa-Rocha, Thais Abdala-Torres, Ana Carolina Campi-Azevedo, Vanessa Peruhype-Magalhães, Márcio Sobreira Silva Araújo, Elaine Spezialli, Lis Ribeiro Do Valle Antonelli, Rosiane Aparecida da Silva-Pereira, Gregório Guilherme Almeida, et al.

    The present study aimed at evaluating the YF-specific neutralizing antibody profile besides a multiparametric analysis of phenotypic/functional features of cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF vaccine, administered as a single subcutaneous injection. The immunological parameters of each volunteer was monitored at two time points, referred as: before (Day 0) [Non-Vaccinated, NV(D0)] and after vaccination (Day 30–45) [Primary Vaccinees, PV(D30–45)]. Data demonstrated high levels of neutralizing antibodies for PV(D30–45) leading to a seropositivity rate of 93%. A broad increase of systemic soluble mediators with a mixed profile was also observed for PV(D30–45), with IFN-γ and TNF-α presenting the highest baseline fold changes. Integrative network mapping of soluble mediators showed increased correlation numbers in PV(D30–45) as compared to NV(D0) (532vs398). Moreover, PV(D30–45) exhibited increased levels of Terminal Effector (CD45RA+CCR7−) CD4+ and CD8+ T-cells and Non-Classical memory B-cells (IgD+CD27+). Dimensionality reduction of Mass Cytometry data further support these findings. A polyfunctional cytokine profile (TNF-α/IFN-γ/IL-10/IL-17/IL-2) of T and B-cells was observed upon in vitro antigen recall. Mapping and kinetics timeline of soluble mediator signatures for PV(D30–45) further confirmed the polyfunctional profile upon long-term in vitro culture, mediated by increased levels of IFN-γ and TNF-α along with decreased production of IL-10. These findings suggest novel insights of correlates of protection elicited by the 1/5 fractional dose of 17DD-YF vaccine.